Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Interaction between clopidogrel and proton pump inhibitors

Mark H. Friesen
CMAJ June 09, 2009 180 (12) 1228; DOI: https://doi.org/10.1503/cmaj.1090014
Mark H. Friesen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The study by David Juurlink and colleagues is a significant contribution to the awareness of potential interactions between clopidogrel and proton pump inhibitors. 1 However, a number of important issues limit the general applicability of the study to clinical practice.

Results from a case–control study do not seem to warrant statements regarding causation. For example, the authors stated, “We estimated that about 7.4% of readmissions because of reinfarction … occurred as the result of concomitant therapy with these agents.” 1 Although this study does suggest an association between concomitant therapy and risk of reinfarction, the authors did not demonstrate causation. Higher odds ratios (e.g., > 2) are generally required before the results of case–control studies can be seen to indicate real risk. 2

The authors did not address studies that have reported results that contradict theirs. Although they correctly indicated that Simon and colleagues 3 demonstrated the effect of genetic polymorphisms on clopidogrel, they failed to mention the lack of association between proton pump inhibitors and major cardiovascular events in this study. Although they correctly indicated that Aubert and colleagues 4 demonstrated an increased risk with proton pump inhibitors, they failed to cite another abstract from the same scientific session that found that the benefit of clopidogrel was not diminished by baseline use of proton pump inhibitors. 5 This latter report is of particular interest because it was an analysis of a randomized controlled trial that would have provided better control of confounders than the case–control study by Juurlink and colleagues.

The authors did not indicate whether all 3 of the proton pump inhibitors in their study contributed equally to the reported odds ratio of 1.40 for risk of recurrent myocardial infarction within 90 days of hospital discharge. A reasonable case could be made that rabeprazole is sufficiently different from the other 2 agents to justify separate analysis. Both lansoprazole and omeprazole have been shown to inhibit the antiplatelet activity of clopidogrel in vivo. 6,7 To date, no such study has been reported for rabeprazole. In contrast with omeprazole and lansoprazole, rabeprazole is not a potent in vitro inhibitor of cytochrome P450 2C19. 8 In contrast with omeprazole, rabeprazole showed no inhibition in the metabolism of diazepam, a substrate for cytochrome P450 2C19. 9 Although the metabolite rabeprazole thioether is a potent in vitro inhibitor of cytochrome P450 2C19, its concentration in vivo is about 30% of that of its parent compound. 8,10 Given these differences, it is far from clear that rabeprazole would exhibit an interaction potential with clopidogrel comparable to that of omeprazole and lansoprazole.

Footnotes

  • Competing interests: None declared.

REFERENCES

  1. 1.↵
    Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713–8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Levine M, Waiter S, Lee H, et al. Users’ guides to the medical literature IV. How to use an article about harm. JAMA 1994;271:1615–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular response. N Engl J Med 2009;360: 363–75.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation 2008;118:S_815.
  5. 5.↵
    Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118:S_815.
  6. 6.↵
    Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475–84.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256–60.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4’-hydroxylation. Clin Pharmacol Ther 1995;58:155–64.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Setoyama T, Drijfhout WJ, van de Merbel NC, et al. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. Int J Clin Pharmacol Ther 2006;44:557–65.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 180 (12)
CMAJ
Vol. 180, Issue 12
9 Jun 2009
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interaction between clopidogrel and proton pump inhibitors
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Interaction between clopidogrel and proton pump inhibitors
Mark H. Friesen
CMAJ Jun 2009, 180 (12) 1228; DOI: 10.1503/cmaj.1090014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Interaction between clopidogrel and proton pump inhibitors
Mark H. Friesen
CMAJ Jun 2009, 180 (12) 1228; DOI: 10.1503/cmaj.1090014
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Feasibility of screening for anal cancer in HIV-positive people older than 50 years in Canada
  • An old–new problem: alcohol use among medical students
  • Role of dietitians in reducing malnutrition in hospital
Show more Letters

Similar Articles

Content

  • Current issue
  • Past issues
  • Early releases
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Media
  • Permission requests
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2018, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire